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and bloodstream infections (BSI) for several years. We eval-
uated the in vitro activity of daptomycin and comparators
against recent (2006) clinical isolates collected in 5 Asia-
Paciﬁc (APAC) countries.
Methods: 523 consecutive strains were collected in (no.
of strains; medical centers) Hong Kong (100; 1), Indone-
sia (63; 3), Philippines (124; 2), Singapore (119; 1) and
Thailand (117; 2). Most isolates were from cSSTI and BSI.
Organisms evaluated included: S. aureus (SA; 326 strains);
coagulase-negative staphylococci (CoNS; 31), enterococci
(92), viridans group streptococci (VGS; 32) and -haemolytic
streptococci (BHS; 42). Antimicrobial susceptibility was
evaluated by reference broth microdilution methods in
cation-adjusted Mueller-Hinton broth with 50mg/L of cal-
cium for daptomycin tests.
Results: Daptomycin was highly active against SA (100.0%
susceptibility) with minor variations among countries.
Among SA, oxacillin resistance varied from 29.6% in Thailand
to 80.4% in Singapore; while the highest rates of resis-
tance to clindamycin and trimethoprim/sulfamethoxazole
were observed in Indonesia (46.9 and 59.6% respectively),
Thailand (28.3 and 39.1%) and Singapore (29.6 and 31.5%).
Daptomycin inhibited all CoNS strains at ≤1mg/L or less
and was two- to four-fold more potent than vancomycin or
linezolid against SA and CoNS. Enterococci were also very
susceptible to daptomycin (MIC50/90, 1/4mg/L; 100.0% sus-
ceptible) and vancomycin resistance was observed only in
Thailand (2.0%, VRE). VGS and BHS strains showed lower dap-
tomycin MIC values (MIC90, 1 and 0.25mg/L respectively).
Conclusions: Antimicrobial susceptibility patterns of
Gram-positive organisms varied substantially among the
APAC nations evaluated and daptomycin exhibited complete
coverage (100.0% susceptibility) and high potency against a
large collection of contemporary clinical strains collected in
9 hospitals from 5 APAC countries.
doi:10.1016/j.ijid.2008.05.721
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Background: Daptomycin, a novel cyclic lipopeptide,
exhibits a unique mechanism of action that includes binding
to, and depolarizing, the bacterial membrane resulting in
rapid loss of cellular function and cell death. We evaluated
the in vitro activity of daptomycin against recent clinical
isolates collected in ten Chinese hospitals.
Methods: 924 consecutive strains were collected in Chi-
nese medical centers in 2006. The organisms, one per
patient, were isolated mainly from bloodstream and skin
and soft tissue infections. The following pathogens were
evaluated: S. aureus (SA; 37.5% oxacillin-resistant [MRSA]);
coagulase-negative staphylococci (CoNS; 88.9% oxacillin-
resistant), Enterococcus spp. (0.5% vancomycin-resistant
[VRE]) and viridans group streptococci (VGS; 43.8 penicillin-
susceptible). The strains were susceptibility tested by broth
microdilution methods in cation-adjusted Mueller-Hinton
broth supplemented to 50mg/L of calcium for daptomycin
tests. Numerous comparator agents were tested.
Results: All organisms tested were considered suscepti-
ble to daptomycin. Daptomycin was highly active against
SA (MIC90, 0.5mg/L) and CoNS (MIC90, 1mg/L), and two- to
four-fold more potent than vancomycin or linezolid against
these organisms. MRSA showed high rates of resistance to
clindamycin (92.4%), levoﬂoxacin (96.2%) and gentamicin
(95.5%), and daptomycin MIC values slightly higher com-
pared to oxacillin-susceptible SA. All enterococcal strains
were inhibited at the daptomycin susceptible breakpoint of
≤4mg/L, including a few VRE strains. E. faecalis (MIC90,
2mg/L) exhibited daptomycin MIC values lower than E.
faecium (MIC90, 4mg/L). Quinupristin/dalfopristin showed
limited activity (61.7% susceptibility) against E. faecium;
and E. faecalis showed high rate of high-level resistance
to gentamicin (49.8%) and streptomycin (51.7). Daptomycin
was very active against VGS (MIC90, 0.5mg/L).
Conclusions: Daptomycin showed signiﬁcant potency and
broad-spectrum activity against recent clinical isolates
of Gram-positive organisms isolated in Chinese medical
centers, including multidrug-resistant subsets. All Gram-
positive organisms tested were susceptible to daptomycin.
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Objectives: Worldwide methicillin-resistant S.aureus
(MRSA) are increasing dramatically with corresponding resis-
tance to multiple drug classes (MDR). Tigecycline, a new
glycylcycline offers the potential of enhanced activity
against MDR S. aureus. The tigecycline evaluation surveil-
lance trial (T.E.S.T.) evaluated the activity of tigecycline
and comparators to MDR S. aureus(including MR+MS strains)
isolated in the United States.
Methods: 193 hospital sites in the United States, between
2004 and 2007, collected 5280 clinically signiﬁcant S.
aureus. MICs were performed as speciﬁed by CLSI at each
site.
Results: MIC90 of tigecycline and comparators to S. aureus
resistant groups 0—3+ are shown in the following table:
Conclusions: Tigecycline demonstrated in vitro activity
comparable to that of linezolid and vancomycin against all
multidrug resistant groups of S. aureus. Tigecycline in vitro
activity is unaffected by multidrug resistant phenotypes of
S. aureus and offers an alternative in the treatment of infec-
tions due to S. aureus where approved indications apply.
doi:10.1016/j.ijid.2008.05.723
